Physician profile
Emily E Tilley
NPI 1487423539
$654.25
in general payments reported to CMS, 2019-2025
11 companies · $597 in 2025
The $597 reported for 2025 was more than what 76% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $57.12 · 2025: $597.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $654.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $654.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $300.07 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $140.15 | 2025 | Airsupra |
| Pfizer INC. | $36.82 | 2025 | |
| Lilly USA, LLC | $32.62 | 2025 | Mounjaro, Zepbound |
| Axsome Therapeutics, INC. | $26.44 | 2025 | Auvelity |
| Dynavax Technologies Corporation | $21.44 | 2025 | Heplisav-B |
| Qol Medical, LLC | $20.69 | 2024 | Sucraid |
| Novo Nordisk INC | $19.80 | 2024 | Rybelsus, Ozempic |
| Exact Sciences Corporation | $19.74 | 2025 | The Cologuard Plus Collection Kit |
| Merck Sharp & Dohme LLC | $19.24 | 2025 | Vaxneuvance, Enflonsia, Gardasil 9 |
| Glaxosmithkline, LLC. | $17.24 | 2025 | Shingrix, Arexvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Tilley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.